MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-06-2026
Mettler-Toledo International Retained Earnings 2011-2026 | MTD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Mettler-Toledo International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.24 B | 8.37 B | 7.51 B | 6.73 B | 5.86 B | 5.1 B | 4.5 B | 3.94 B | 3.43 B | 3.07 B | 2.69 B | 2.36 B | 2.04 B | 1.75 B | 1.48 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.24 B | 1.48 B | 4.54 B |
Quarterly Retained Earnings Mettler-Toledo International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.95 B | 8.74 B | 8.53 B | 8.37 B | 8.12 B | 7.91 B | - | 7.51 B | 7.33 B | 7.13 B | 6.91 B | 6.73 B | 6.46 B | - | 6.03 B | 5.86 B | 5.63 B | 5.43 B | 5.24 B | 5.1 B | 5.1 B | 5.1 B | 5.1 B | 4.5 B | 4.5 B | 4.5 B | 4.5 B | 3.94 B | 3.94 B | 3.94 B | 3.94 B | 3.43 B | 3.43 B | 3.43 B | 3.16 B | 3.07 B | 3.07 B | 3.07 B | 3.07 B | 2.69 B | 2.69 B | 2.69 B | 2.69 B | 2.36 B | 2.36 B | 2.36 B | 2.36 B | 2.04 B | 2.04 B | 2.04 B | 2.04 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.95 B | 1.48 B | 4.25 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
Celcuity
CELC
|
-272 M | $ 107.62 | -0.63 % | $ 4.25 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 13.82 | -2.68 % | $ 418 M | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
-200 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 175.77 | -1.61 % | $ 8.71 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
6.39 B | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
680 M | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K |  Israel |
|
Biodesix
BDSX
|
-462 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
-30.5 M | $ 13.37 | -3.47 % | $ 328 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 204.04 | -0.9 % | $ 145 B | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
OPKO Health
OPK
|
-2.07 B | $ 1.22 | -2.02 % | $ 847 M | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
-322 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 10.3 | -4.19 % | $ 292 M | Israel |
 |
DexCom
DXCM
|
2.43 B | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
6.05 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
-16.8 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-98.2 M | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
-600 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
-1.24 B | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
Renalytix AI plc
RNLX
|
-212 M | - | 5.66 % | $ 22.7 M | Britain |
 |
VolitionRx Limited
VNRX
|
-230 M | $ 0.2 | -0.74 % | $ 19.2 M |  Singapore |